FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST.
Marianne VogsenJakob Lykke BülowLasse LjungstrømHjalte Rasmus OltmannTural Asgharzadeh AlamdariMohammad Naghavi-BehzadPoul-Erik BraadOke GerkeMalene Grubbe HildebrandtPublished in: Diagnostics (Basel, Switzerland) (2021)
PERCIST, with the introduction of PERCISTnadir, allows a graphical interpretation of disease fluctuation that may be beneficial in clinical decision-making regarding potential earlier termination of non-effective toxic treatment. PERCIST seems feasible for response monitoring in MBC but prospective studies are needed to come this closer.
Keyphrases